Acer Therapeutics Inc. Stock News

Here is how Opexa Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.

NEWTON, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for seriou

NEWTON, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious

Acer Therapeutics (NASDAQ:ACER) and CV Sciences (OTCMKTS:CVSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Profitability This table compares Acer Therapeutics and CV Sciences net margins, return on equity and []

Phase 2a trial initiation expected in Q1 2022

Phase 2a trial initiation expected in Q1 2022

Acer Therapeutics (NASDAQ:ACER) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The companys product pipeline consists of []

Equities analysts expect that Acer Therapeutics Inc. (NASDAQ:ACER) will announce earnings of ($0.24) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Acer Therapeutics earnings. The lowest EPS estimate is ($0.25) and the highest is ($0.22). Acer Therapeutics posted earnings of ($0.50) per share during the same []

Vanguard Group Inc. grew its stake in shares of Acer Therapeutics Inc. (NASDAQ:ACER) by 6.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 179,143 shares of the biopharmaceutical companys stock after acquiring an additional 11,094 shares during the period. [] The post Vanguard Group Inc. Boosts Stock Holdings in Acer Therapeutics Inc. (NASDAQ:ACER) appeared first on ETF Daily News .